RoslinCT vs SCTbio: CDMO Comparison
How does RoslinCT compare to SCTbio for CAR-T manufacturing?
Side-by-side comparison of RoslinCT and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- RoslinCT has FDA inspections on record (1); SCTbio does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- SCTbio holds 5 active EMA GMP certificates; RoslinCT does not appear in EudraGMDP.
- RoslinCT maintains 1 MHRA / UK GMP certificate; SCTbio does not.
On a 13-modality CDMO landscape, both RoslinCT and SCTbio qualify as CAR-T manufacturers; SCTbio carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both RoslinCT and SCTbio qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: RoslinCT vs SCTbio
How does RoslinCT compare to SCTbio for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, RoslinCT is 80/100 and SCTbio is 82/100; RoslinCT has 1 FDA inspection on record vs 0 for SCTbio; European coverage is 1 active EMA+MHRA certificate for RoslinCT vs 5 for SCTbio. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, RoslinCT or SCTbio?
Both RoslinCT and SCTbio maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. RoslinCT has 1 FDA inspection on record; SCTbio has 0.
How do RoslinCT and SCTbio compare on European GMP coverage?
RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for CAR-T manufacturing — RoslinCT or SCTbio?
Both RoslinCT and SCTbio are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
RoslinCT carries a Signal Score of 80/100 and SCTbio carries 82/100 — essentially tied for SCTbio. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →